Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance

被引：36

作者：

Apostolaki, Stella ^{[1
]}

Perraki, Maria ^{[1
]}

Kallergi, Galatea ^{[2
]}

Kafousi, Maria ^{[3
]}

Papadopoulos, Savvas ^{[4
]}

Kotsakis, Athanasios ^{[5
]}

Pallis, Athanasios ^{[5
]}

Xenidis, Nikolaos ^{[5
]}

Kalmanti, Lyda ^{[5
]}

Kalbakis, Kostas ^{[5
]}

Agelaki, Sofia ^{[5
]}

Kalykaki, Antonia ^{[5
]}

Stournaras, Christos ^{[2
]}

Stathopoulos, Efstathios ^{[3
]}

Georgoulias, Vassilis ^{[1
,5
]}

Mavroudis, Dimitris ^{[1
,5
]}

机构：

[1] Univ Crete, Tumor Cell Biol Lab, Sch Med, Iraklion, Crete, Greece

[2] Univ Crete, Sch Med, Dept Biochem, Iraklion, Crete, Greece

[3] Univ Gen Hosp Heraklion, Dept Pathol, Iraklion 71110, Crete, Greece

[4] Ygeia Hosp, Dept Pathol, Athens, Greece

[5] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion 71110, Crete, Greece

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2009年 / 117卷 / 03期

关键词：

HER2; mRNA; Breast cancer; Circulating tumor cells; Prognosis; POLYMERASE-CHAIN-REACTION; BONE-MARROW; STAGE-I; ADJUVANT CHEMOTHERAPY; MOLECULAR-DETECTION; NEU ONCOGENE; FOLLOW-UP; GENE; OVEREXPRESSION; AMPLIFICATION;

D O I：

10.1007/s10549-008-0239-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate whether HER2 mRNA could be used as a marker of circulating tumor cells (CTCs) in women with operable breast cancer. A nested RT-PCR assay was developed and used for the detection of HER2 mRNA-positive CTCs. Blood from 216 women with early breast cancer obtained before adjuvant treatment was tested for HER2 mRNA-positive cells to assess their prognostic value. Nested RT-PCR for HER2 mRNA showed high sensitivity whereas no HER2 mRNA-positive cells could be identified in the blood of healthy donors. HER2 mRNA-positive CTCs were detected in 53 (24.5%) of 216 patients and HER2 mRNA detection was associated with reduced disease-free survival (DFS; P < 0.0001) and overall survival (OS; P = 0.004). In multivariate analysis, detection of HER2 mRNA-positive CTCs emerged as independent prognostic factor for DFS (P = 0.0001) and OS (P = 0.003). HER2 mRNA could be a valuable prognostic marker for the detection of CTCs in early breast cancer patients.

引用

页码：525 / 534

页数：10

共 31 条

[1] Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance [J].

Apostolaki, S. ;

Perraki, M. ;

Pallis, A. ;

Bozionelou, V. ;

Agelaki, S. ;

Kanellou, P. ;

Kotsakis, A. ;

Politaki, E. ;

Kalbakis, K. ;

Kalykaki, A. ;

Vamvakas, L. ;

Georgoulias, V. ;

Mavroudis, D. .

ANNALS OF ONCOLOGY, 2007, 18 (05) :851-858

[2]

Armitage P., 2001, STAT METHODS MED RES, V4th

[3] Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer [J].

Bozionellou, V ;

Mavroudis, D ;

Perraki, M ;

Papadopotilos, S ;

Apostolaki, S ;

Stathopoulos, E ;

Stathopoulou, A ;

Lianidou, E ;

Georgoulias, V .

CLINICAL CANCER RESEARCH, 2004, 10 (24) :8185-8194

[4]

Brandt B, 1998, INT J CANCER, V76, P824, DOI 10.1002/(SICI)1097-0215(19980610)76:6<824::AID-IJC10>3.0.CO

[5]

2-2

[6] Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].

Braun, S ;

Pantel, K ;

Muller, P ;

Janni, W ;

Hepp, F ;

Kentenich, CRM ;

Gastroph, S ;

Wischnik, A ;

Dimpfl, T ;

Kindermann, G ;

Riethmuller, G ;

Schlimok, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533

[7]

Braun S, 2001, CANCER RES, V61, P1890

[8] A pooled analysis of bone marrow micrometastasis in breast cancer [J].

Braun, S ;

Vogl, FD ;

Naume, B ;

Janni, W ;

Osborne, MP ;

Coombes, RC ;

Schlimok, G ;

Diel, IJ ;

Gerber, B ;

Gebauer, G ;

Pierga, JY ;

Marth, C ;

Oruzio, D ;

Wiedswang, G ;

Solomayer, EF ;

Kundt, G ;

Strobl, B ;

Fehm, T ;

Wong, GYC ;

Bliss, J ;

Vincent-Salomon, A ;

Pantel, K .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :793-802

[9] Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients [J].

Braun, S ;

Kentenich, C ;

Janni, W ;

Hepp, F ;

de Waal, J ;

Willgeroth, F ;

Sommer, H ;

Pantel, K .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :80-86

[10] Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal [J].

Diel, IJ ;

Kaufmann, M ;

Costa, SD ;

Holle, R ;

vonMinckwitz, G ;

Solomayer, EF ;

Kaul, S ;

Bastert, G .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (22) :1652-1658

← 1 2 3 4 →